EXCLUSIVE: Prince William and Kate Middleton's relationship with Prince Andrew has been strained for years, with new royal ...

Seattle just poached a highly regarded Ravens staffer in a “sneaky big” move. Here’s what he worked on in Baltimore, and why it matters now.

Upstream Bio stock fell after mixed asthma drug data, but analysts say the selloff may be overdone despite competition concerns.

Another factor related to their length is that they tend to form very complex structures, with many different areas of the ...

Ai-jen Poo and Lydia Storie have launched Give Not Take Media, a new label that will major in film and TV projects about care ...

A phase 2 asthma study of Upstream Bio’s TSLP receptor agonist has hit its primary endpoint. But with only the 12-week ...

RNA-based medicine is about to take a huge leap forward thanks to the discovery of extremely short RNA fragments with ...

By Published If you or members of your book club can’t seem to get through long, heavy reads, we have some options for you: short biographies, essays, histories and other unique works of nonfiction ...

・The latest findings include RNA-sequencing data showing that GRI-0621 significantly modulated genes associated with lung injury. ・Prior Phase 2a results had already shown favorable safety and ...

While Zenas’ obexelimab hit the primary endpoint in the Phase III INDIGO study, it came far below the efficacy threshold set by Amgen’s B cell depleter Uplizna, approved by the FDA for IgG4-related ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.